Rapid Antiretroviral Treatment Initiation With BIC/FTC/TAF in HIV-infected People Who Inject Drugs (PWID)

NCT ID: NCT07004933

Last Updated: 2025-06-04

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 37 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2021-12-22
• Study Completion Date: 2024-12-09

Brief Summary

The goal of this clinical study is to evaluate the effectiveness, safety and patient experience of an integrated care pathway combining rapid antiretroviral (ART) initiation with BIC/FTC/TAF and peer navigation for treatment naïve newly-diagnosed or relinking HIV-infected PWIDs, in terms of viral suppression rates, adverse events and patient-reported health outcomes (PROs).

The main objectives of the study are the assessment of:

• The viral suppression rates at 24 weeks after the rapid initiation of ART with BIC/FTC/TAF coupled with secured peer-navigation in adult HIV-positive PWID who are treatment-naïve or re-linking to care
• The safety and tolerability of BIC/FTC/TAF in the specific context of rapid ART initiation in adult PWID who are treatment-naïve or re-linking to care from baseline until Week 24. Patients will receive their medication according to the standard of care and will visit the clinic as usual. No extra visits or extra lab tests will be performed.

Detailed Description

Taking into account the increased rates of new cases of HIV infection among people who inject drugs (PWID) in Greece, it is proposed the conduct of the observational study with the aim to assess whether clinical outcomes can be improved by the implementation of rapid ART initiation in newly diagnosed HIV-positive PWIDs and re-linking to care previously diagnosed HIV-positive PWIDs with a suitable medication, such as BIC/FTC/TAF, combined with peer-navigation support that can help the afflicted patients overcome social barriers and challenges. Therefore, this pilot study aims to evaluate the effectiveness, safety and patient experience of an integrated care pathway combining rapid ART initiation with BIC/FTC/TAF and peer navigation for treatment naïve newly-diagnosed or relinking HIV-infected PWIDs, in terms of viral suppression rates, adverse events and patient-reported health outcomes (PROs). Given the armamentarium of potent ART regimens, HIV infection has been transformed from a terminal illness into a chronic condition, thus, evaluating the impact of ARTs from patients' perspective is increasingly used [17]. The results of this study are expected to contribute towards informed health policy practices, accelerating and ameliorating care and providing the basis to curb the HIV epidemic and bringing us closer to its end.

Conditions

HIV Positive People Who Inject Drugs

Study Design

• Observational Model Type: OTHER
• Study Time Perspective: PROSPECTIVE

Study Groups

Newly diagnosed- and re-linking to care previously- diagnosed HIV-positive subjects

HIV-positive PWID (people who inject drugs) subjects that enroll in the study within 7 days from the first visit in the clinic and are treatment-naïve or have discontinued antiretroviral treatment (ART) for more than 3 months from enrollment.

bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF)

Intervention Type: DRUG

Rapid antiretroviral treatment initiation with BIC/FTC/TAF

Interventions

bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF)

Rapid antiretroviral treatment initiation with BIC/FTC/TAF

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male or female PWID subjects ≥18 years old

2. Documented and confirmed diagnosis of HIV infection

3. Naïve to ART or having discontinued ART for more than 3 months and relinking to care without documented resistance to any of the components of BIC/FTC/TAF or having missed more than once during the last 12 months, their monthly appointment for ART prescription renewal.

4. Willingness of patients to start OST or already being in OST.

5. Subjects willing and able to understand and provide written informed consent prior to participation in the study.

6. Females may be eligible for enrolment if they are i) of non-child-bearing potential or ii) if they are of child-bearing potential must have a negative pregnancy test at initial screening and agree to use throughout the study a medically acceptable method of contraception (barrier and/or hormonal method) or iii) are sterilized.

Exclusion Criteria

1. Centers for Disease Control and Prevention Category C at baseline or presenting with clinical symptoms suggestive of opportunistic infections precluding rapid ART initiation per EACS guidelines 2020.

2. Alanine aminotransferase (ALT) >5 times upper limit normal (ULN) - Subjects with severe hepatic impairment (Child-Pugh score>9).

3. eGFR<30 ml/min

4. Any serious medical condition which would compromise the safety of the subject. Subject has a pre-existing mental, physical, or severe substance abuse disorder that may interfere with the subject's ability to comply with the dosing schedule and protocol evaluations and assessments. Subject has a condition or disorder which may interfere with drug absorption or render the subject unable to take oral medication.

5. Subject is, in the opinion of the Investigator, unable to complete the study dosing period and protocol evaluations and assessments. Patients with alcohol and drug use problems that in the view of the Investigator will compromise participation in the study.

6. Subject has any acute laboratory abnormality at screening, which, in the opinion of the Investigator, would preclude the subject's participation in the study. Any verified grade 4 abnormality would exclude a subject from participation in the study.

7. Subject is receiving or has received within 14 days prior to screening, any drug that has been classified as contraindicated from use with BIC/FTC/TAF

8. Pregnant or breast-feeding subjects.

9. Participation in another clinical trial.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Gilead Sciences

INDUSTRY

Sponsor Role: collaborator

Hellenic Scientific Society for the Study of AIDS, Sexually Transmitted and Emerging Diseases

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Mina Psichogiou, Professor

Role: PRINCIPAL_INVESTIGATOR

General Hospital of Athens "LAIKO"

Locations

General Hospital of Athens "EVAGGELISMOS"

Athens, Attica, Greece

General Hospital of Athens "LAIKO"

Athens, Attica, Greece

University General Hospital "ATTIKON"

Athens, Attica, Greece

Countries

Greece

Other Identifiers

BFTAFDU-1

Identifier Type: -

Identifier Source: org_study_id